EU OKs Merck/Schering deal
This article was originally published in The Tan Sheet
The European Commission Oct. 23 approves the pending Merck/Schering-Plough merger, and the firms say they expect the transaction to close this year. During Merck's fiscal 2009 third-quarter earnings call Oct. 22, Merck President and CEO Richard Clark told analysts the firm's OTC joint venture with Johnson & Johnson, which covers U.S. and Canadian business, will remain separate from the Merck/Schering business, but he declined to say whether possible switches of Schering's existing OTC products would have to go through the joint venture. Pending U.S. regulatory approval, Merck will purchase S-P for $41.1 billion (1"The Tan Sheet" March 16, 2009). ... Schering consumer sales flat: MiraLAX sales nearly doubled in the third quarter to $31 million and the laxative is "running neck and neck" with Procter & Gamble's Metamucil, Schering CFO Robert Bertolini says Oct. 22. But the consumer health care business grew only 2 percent to $282 million, hampered by lower sales of OTC Claritin (down 7 percent), sun care (down 19 percent) and foot care (down 5 percent), the Kenilworth, N.J., firm said. Net sales in the July-September period dipped 2 percent to $4.5 billion, and net income fell 17 percent to $477 million
You may also be interested in...
Merck stands to pick up the switch rights to the proton pump inhibitor Zegerid at the head of a strong switch program if its planned acquisition of Schering-Plough succeeds
EU High Court Is ‘Indifferent To Modern Values’; Reactions To Cosmetic Ingredient Animal-Testing Decision
The Cosmetic Products Regulation’s “once groundbreaking” ban is now worthless, says PETA, which supported Symrise in two cases challenging animal testing required by the European Chemicals Agency for cosmetics-only ingredients under REACH. Cruelty Free Europe, the European Federation for Cosmetic Ingredients, and Unilever also intervened on Symrise’s behalf.
Granger’s exit means House Appropriations will have different chair no matter which party wins majority 2024 elections; Democrats will lose senior House Energy and Commerce Health Subcommittee member with Eshoo’s retirement.